| CAS ID: | 34787-01-4 |
| Molecular Formula: | C15H16N2O6S2 |
| Molecular Weight: | 384.4 g/mol |
| Monoisotopic Mass: | 384.045 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | BRL 2288 | TICAR | TICARCILLIN | TICARCILLIN SODIUM | TICARCILLIN MONOSODIUM | TICARCILLIN DISODIUM |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1 | See All |
| InChI Key: | OHKOGUYZJXTSFX-KZFFXBSXSA-N | |
| Smiles: | CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(=O)O)c3ccsc3)C(=O)N2[C@H]1C(=O)O | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 22018680 | Target ID | |
| Uniprot ID | Name | ||
| Model | human | Fibrosis Disease | Cystic fibrosis |
| Process I | |||
| Process II | |||
| Process III | |||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT00153634 | Disease | Cystic fibrosis |
| Phase | Not Applicable | Status | Completed |
| First Received | September 12, 2005 | Last Verified | March 13, 2008 |
| Sponsor | Seattle Children's Hospital | ||
| PubChem: | 36921 |
| ChEMBL: | CHEMBL1449 |